Cord Blood Banking Services Market Assessment, By Component [Cord Blood, Cord Tissue], By Service [Collection and Transportation, Processing, Analysis, Storage], By Application [Oncology, Diabetes, Blood Disease, Immune Disorders, Metabolic Disorders, Oth

Cord Blood Banking Services Market Assessment, By Component [Cord Blood, Cord Tissue], By Service [Collection and Transportation, Processing, Analysis, Storage], By Application [Oncology, Diabetes, Blood Disease, Immune Disorders, Metabolic Disorders, Others], By Bank Type [Public Cord Blood Banks, Private Cord Blood Banks], By End-user [Hospital, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes], By Region, Opportunities and Forecast, 2017-2031F

Global major depressive disorder market stood at USD 12.25 billion in 2023 and is expected to reach USD 16.68 billion by 2031, growing at a CAGR of 3.93% during the forecast period. Major depressive disorder is a common and serious mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. It can affect sleep, appetite, and overall functioning. Treatment options include psychotherapy (such as cognitive-behavioral therapy), antidepressant medications like Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), and lifestyle changes (including exercise and nutrition). In some cases, advanced treatments like transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT) may be considered resistant cases. The market for pharmaceuticals and medical devices used to treat MDD is anticipated to grow during the forecast period due to various types of development, such as growing emphasis and clinical implications around mental health. Along with that, growing investments in the market, regulatory initiatives, and combined efforts of various stakeholders to boost the market's growth rate are anticipated to make huge changes in the future.

In August 2023, Biogen Inc. and Sage Therapeutics, Inc. announced the approval of ZURZUVAE (zuranolone) 50 mg by the US Food and Drug Administration (FDA). This medication is designed to treat postpartum depression (PPD) in adults. ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can rapidly improve depressive symptoms in women with PPD. Additionally, the FDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder.

Biogen Inc. and Sage Therapeutics, Inc. announced the approval of ZURZUVAE (zuranolone) 50 mg by the US Food and Drug Administration (FDA). This medication is designed to treat postpartum depression (PPD) in adults. ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can rapidly improve depressive symptoms in women with PPD. Additionally, the FDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder.

Rising Cases and Emphasis on Mental Health to Boost Market Demand

Major depressive disorder cases have been on the rise recently, which tends to elevate market demand for mental health solutions. The new understanding of mental health issues today eliminates the stigma while encouraging more individuals to seek treatment. Healthcare providers and pharmaceutical companies tend to concentrate their efforts on innovative therapies and holistic approaches, including psychotherapy, digital health solutions, and new treatments. The COVID-19 pandemic has also increased mental health issues. The cases of reported depression are on the rise, and effective interventions require better programs for mental health. Government initiatives towards increasing mental health program funding have also helped fuel this growth. As there is more understanding about mental health, the demand for more tailored and accessible options for treatment will drive the market towards significant growth over the next few years.

For instance, according to an article published in Signal Transduction and Targeted Therapy Journal in February 2024, the prevalence of depression is increasing every year. Approximately 300 million people worldwide are affected by major depressive disorder, making it one of the leading causes of disability. In 2018, MDD ranked third in terms of disease burden according to the World Health Organization (WHO), and it is predicted to become the leading cause by 2030.

Government Initiatives to Major Depressive Disorder Drives Market Growth

With the increasing interest of investors in the treatment of major depressive disorder, business increases due to higher investment in research and development of new treatments, such as pharmaceuticals and digital health solutions. With increased innovation rates, this more rapidly delivers greater diversity and effectiveness in therapies as well as personalization of treatment. Companies respond to the increased demand by offering more products, while competition helps bring down costs, enhancing patient care access. In addition, investors tend to encourage collaboration between biotechnology firms, research institutions, and healthcare delivery systems, which maximizes resource sharing and enhances research. Investment in the issues of mental health increases public awareness of mental illness, and the stigmatism associated with the conditions is reduced. Therefore, more individuals can receive help with mental health disorders.

For instance, in July 2024, Autobahn Therapeutics, Inc., a biotech company established from a lab at Oregon Health & Science University, secured USD 100 million in private investment to develop treatments for neuropsychiatric disorders like major depressive disorder and bipolar depression. The funding will advance their pipeline of brain-penetrant small molecules, including a compound targeting major depressive and bipolar depression disorders, which affect over 27 million people in the United States.

Drug Segment Dominates with High Market Share

The dominance of the drug segment in the major depressive disorder market relates to its accessible treatments. The application areas of pharmacological treatments, especially antidepressants of the SSRIs and SNRIs class, are broad in this area. Accessibility is a contributing factor to relatively higher patient adoption rates. Novel drug developments continue to create new formulations and targeted therapy forms that optimize treatment options and attract investments. Moreover, the high prevalence of MDD calls for medication, as most of them are yet to be relieved from the debilitating symptoms. Additionally, medication has been considered the first-line treatment for most healthcare providers, especially in moderate to severe cases, leading to strong market penetration. Regulatory approvals in the market further fuel the growth of the market share of the drug segment.

For instance, in September 2023, Fabre-Kramer Pharmaceuticals Inc., a biopharmaceutical company dedicated to psychiatry and neurology treatments, announced the US FDA approval of its Exxua, a gepirone hydrochloride extended-release tablet intended for the treatment of major depressive disorders in adults. Exxua represents a new class of antidepressants; it is the first and only approved antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion.

North America Dominates Major Depressive Disorder Market

North America holds a dominant position in the major depressive disorder market due to several factors. Firstly, there is a high prevalence of depression, driven by increasing awareness and improved diagnosis, leading to more patients seeking treatment. The region boasts advanced healthcare infrastructure and access to a wide range of treatment options, including innovative therapies and medications. Significant investment in mental health research and development fosters the emergence of new and effective treatments. Major pharmaceutical companies are concentrated in North America, driving competition and innovation. The US FDA plays a crucial role by providing expedited approval pathways for new treatments, which enhances market responsiveness to emerging therapies.

In August 2024, Otsuka Precision Health, Inc. and Click Therapeutics, Inc. launched Rejoyn, the first prescription digital therapeutic for treating major depressive disorder symptoms. The US FDA approved it in March 2024, and it is available for adult patients with MDD aged 22 years and older who are on antidepressant medication. Patients can obtain a prescription for Rejoyn from their current provider or via a virtual consultation from Wheel Health, Inc. BlinkRx is the exclusive pharmacy provider for Rejoyn.

Future Market Scenario (2024-2031F)

Innovative novel drugs that are still in the development stages can expand the major depressive disorder market greatly by establishing innovative lines of treatment, such as efficiency and reduced side effects. Advances in new antidepressants, including fast-acting ketamine and psychedelic chemicals, also give hope to patients who are resistant to conventional treatment options. Such developments improve a patient's outcome and expand the treatment scope, thereby attracting funding and investment for research purposes. In addition, the rising wave of personalized medicine approaches that use genetic and biomarker information in tailoring treatments will further increase the precision of MDD interventions. More advanced innovations regarding understanding the disorder will lead to earlier diagnosis and effective management strategies. Every time a new treatment enters the market, it increases competition and lowers costs, making it available for wider patient populations.

For instance, in July 2024, Johnson & Johnson Services, Inc. submitted a supplemental New Drug Application (sNDA) to the US FDA. They are seeking approval for SPRAVATO (esketamine) CIII nasal spray as a monotherapy for adults with treatment-resistant depression (TRD). It's worth noting that nearly 30% of the estimated 280 million people worldwide living with major depressive disorder have TRD. TRD occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.

Key Players Landscape and Outlook

The market for major depressive disorder is segmented into drugs mainly. The drug market is quite fragmented, with a huge number of players, while the device market is quite consolidated and has a lower share in terms of revenue. Recent market activities include mergers and acquisitions along with innovative product launches.

In August 2024, AbbVie Inc. completed its acquisition of Cerevel Therapeutics Holdings, Inc., enhancing its neuroscience portfolio, particularly in treating major depressive disorder (MDD). Cerevel's pipeline includes CVL-354, a potential kappa opioid receptor antagonist aimed at improving efficacy and tolerability for MDD. This acquisition aligns with AbbVie's strategy to address significant unmet needs in neurological and psychiatric conditions, promising advancements in therapies for patients suffering from these disorders.